Table 2 Top 10 KEGG pathways potentially affected by the differentially expressed miRNAs in each clinical group evaluated: tumor size, LN, and REC status (ranked by p-value)

Tumor size (≥5 cm, < 5 cm)

1

Ubiquitin mediated proteolysis

1.46E-05

40

7

2

Circadian rhythm

0.002970639

14

7

3

Proteoglycans in cancer

0.002970639

42

7

4

Renal cell carcinoma

0.004487894

18

7

5

Signaling pathways regulating pluripotency of stem cells

0.004646529

33

6

6

Endocytosis

0.004646529

44

8

7

Glioma

0.007370446

17

7

8

Oocyte meiosis

0.015388458

25

7

9

RNA degradation

0.022814164

21

6

10

Prolactin signaling pathway

0.022814164

17

6

LN status

1

Mucin type O-Glycan biosynthesis

3.42E-10

14

8

2

Proteoglycans in cancer

6.78E-10

32

9

3

Signaling pathways regulating pluripotency of stem cells

3.68E-07

55

9

4

TGF-beta signaling pathway

3.17E-06

68

8

5

Glycosaminoglycan biosynthesis – heparan sulfate/heparin

5.72E-06

38

7

6

Hippo signaling pathway

6.54E-06

2

2

7

FoxO signaling pathway

6.94E-06

49

8

8

Circadian rhythm

2.90E-05

52

9

9

ErB signaling pathway

3.54E-05

44

9

10

Phosphatidylinositol signaling system

6.34E-05

25

7

REC status

1

Prion diseases

1.07E-05

10

8

2

Proteoglycans in cancer

1.07E-05

91

20

3

Mucin type O-Glycan biosynthesis

1.34E-05

15

12

4

Cell adhesion molecules (CAMs)

1.84E-05

65

18

5

TGF-beta signaling pathway

3.45E-05

40

16

6

Axon guidance

3.45E-05

65

16

7

Oxytocin signaling pathway

0.001164

76

18

8

N-Glycan biosynthesis

0.003947

21

15

9

Thyroid hormone signaling pathway

0.003947

53

19

10

Signaling pathways regulating pluripotency of stem cells

0.004389

65

20